iData Insights

Diphtheria - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 03, 2016 15:15 IST

This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diphtheria - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diphtheria and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects - A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diphtheria pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179117/diphtheria-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179117/diphtheria-pipeline-review-h2-2015

Table of Contents

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 80

Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 80

Jun 13, 2005: U.S. FDA Licenses sanofi pasteurs ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 81

Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 81

Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteurs ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 82

Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. 83

Aug 28, 2000: Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series. 83

Jul 13, 1995: Connaught Laboratories, Inc. Applies to FDA for Licensing of Tripedia for Infant Use 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86" width="80" height="40" />for Review a Biologics License Application for Merck and Sanofi Pasteurs Investigational Pediatric Hexavalent Vaccine 79

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 80

Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 80

Jun 13, 2005: U.S. FDA Licenses sanofi pasteurs ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 81

Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 81

Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteurs ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis 82

Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults. 83

Aug 28, 2000: Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series. 83

Jul 13, 1995: Connaught Laboratories, Inc. Applies to FDA for Licensing of Tripedia for Infant Use 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

Read More http://www.idatainsights.com/reports-landing-page.php?id=179117/diphtheria-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.